Physician profile
J Christensen
NPI 1639158066
$4,849.38
in general payments reported to CMS, 2019-2025
51 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.69 · 2020: $14.12 · 2021: $423 · 2022: $906 · 2023: $1,064 · 2024: $1,083 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,421 · Entertainment: $16.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,421.47 |
| Entertainment | $16.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $816.68 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $546.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $358.28 | 2022-2025 | |
| Lilly USA, LLC | $349.80 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.49 | 2021-2025 | Jardiance |
| Amgen INC. | $249.62 | 2021-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $193.46 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.11 | 2021-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $104.57 | 2022-2025 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $103.26 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $100.36 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $99.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $95.03 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $94.34 | 2020-2024 | Gardasil 9, Gardasil, Capvaxive |
| Eisai INC. | $91.25 | 2021-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.